Bayer: new analyses on heart failure

(CercleFinance.com) - Bayer has announced that new analyses from the phase III FINEARTS-HF trial evaluating finerenone (Kerendia) in heart failure (HF) patients with a left ventricular ejection fraction (LVEF) of ≥ 40% will be presented at the Cardiovascular Clinical Trials Forum (CVCT), which is being held in Washington from December 9 to 11, 2024.


A new FINEARTS-HF analysis assessed the effects of finerenone on systolic blood pressure in patients with heart failure and mildly reduced or preserved ejection fraction.

Additional analyses assessed the impact of finerenone in specific patient subgroups, including those with worsening outpatient heart failure events, as well as patients classified according to variable ejection fraction levels and body mass index ranges.

Another analysis evaluated the effects of finerenone in patients with heart failure. heart failure and slightly reduced or preserved ejection fraction in three phase III clinical trials.

Copyright (c) 2024 CercleFinance.com. All rights reserved.